Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases
Tóm tắt
Matrix metalloproteinases (MMPs), also designated matrixins, hydrolyze components of the extracellular matrix. These proteinases play a central role in many biological processes, such as embryogenesis, normal tissue remodeling, wound healing, and angiogenesis, and in diseases such as atheroma, arthritis, cancer, and tissue ulceration. Currently 23 MMP genes have been identified in humans, and most are multidomain proteins. This review describes the members of the matrixin family and discusses substrate specificity, domain structure and function, the activation of proMMPs, the regulation of matrixin activity by tissue inhibitors of metalloproteinases, and their pathophysiological implication.
Từ khóa
Tài liệu tham khảo
Woessner JF. The matrix metalloproteinase family. In: Parks WC Mecham RP eds. Matrix Metalloproteinases. San Diego Calif: Academic Press; 1998: 1–13.
Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997; 74: 111–122.
Uria JA, López-Otín C. Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. Cancer Res. 2000; 60: 4745–4751.
Velasco G, Cal S, Merlos-Suárez A, Ferrando AA, Alvarez S, Nakano A, Arribas J, López-Otín C. Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors. Cancer Res. 2000; 60: 877–882.
Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem. 1997; 378: 151–160.
Woessner JF Nagase H. Matrix Metalloproteinases and TIMPs. Oxford UK: Oxford University Press; 2000.
Llano E, Pendas AM, Freije JP, Nakano A, Knäuper V, Murphy G, López-Otín C. Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase A overexpressed in brain tumors. Cancer Res. 1999; 59: 2570–2576.
Nagase H. Substrate specificity of MMPs. In: Clendenninn NJ Appelt K eds. Matrix Metalloproteinase Inhibitors in Cancer Therapy. Totowa NJ: Humana Press Inc; 2001: 39–66.
Tabata Y, Isashiki Y, Kamimura K, Nakao K, Ohba N. A novel splice site mutation in the tissue inhibitor of the metalloproteinases-3 gene in Sorsby’s fundus dystrophy with unusual clinical features. Hum Genet. 1998; 103: 179–182.
Lin HC, Chang JH, Jain S, Gabison EE, Kure T, Kato T, Fukai N, Azar DT. Matrilysin cleavage of corneal collagen type XVIII NC1 domain and generation of a 28-kDa fragment. Invest Ophthalmol Vis Sci. 2001; 42: 2517–2524.
Kadono Y, Okada Y, Namiki M, Seiki M, Sato H. Transformation of epithelial Madin-Darby canine kidney cells with p60(v-src) induces expression of membrane-type 1 matrix metalloproteinase and invasiveness. Cancer Res. 1998; 58: 2240–2244.
Sheu BC, Hsu SM, Ho HN, Lien HC, Huang SC, Lin RH. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res. 2001; 61: 237–242.